跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IRF5
首页
药物
IRF5
IRF5
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
TGFB2-IRF5 THERAPEUTICS FOR CANCER
EP 4720299 A1
申请人: GMP BIOTECHNOLOGY LTD
优先权: 2023
CN
EP
US
WO
4 件公开
Cell penetrating peptides that inhibit IRF5 nuclear localization
US 11130790 B2
申请人: UNIV RUTGERS
优先权: 2019
US
4 件公开
INTERFERON REGULATORY FACTOR 5 INHIBITORS AND USES THEREOF
EP 3966232 A4
申请人: FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
优先权: 2019
EP
US
3 件公开
Method of treating severe asthma
US 10420792 B2
申请人: UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
优先权: 2018
US
3 件公开
NOX2 AS A BIOMARKER OF RADIOTHERAPY EFFICIENCY IN CANCER PATIENTS
EP 3516076 A1
申请人: ROUSSY INST GUSTAVE
优先权: 2016
EP
US
2 件公开
Modulators of IRF5 expression
US 11208650 B2
申请人: IONIS PHARMACEUTICALS INC
优先权: 2018
CN
US
2 件公开
ANTI-CANCER AGENTS
US 20250270560 A1
申请人: GMP BIOTECHNOLOGY LTD
优先权: 2022
CN
US
2 件公开
GENETIC TESTING FOR EARLY DETECTION OF AUTOIMMUNE DISEASES
US 20260226547 A1
申请人: NEW YORK SOC FOR THE RELIEF OF THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL S
优先权: 2023
US
WO
2 件公开
Treatment And Screening
US 2014030218 A1
申请人: UDALOVA IRINA ALEXANDROVNA
优先权: 2012
US
Cell penetrating peptides which bind irf5
CN 104736556 A
申请人: HOFFMANN LA ROCHE
优先权: 2013
CN
第 1 / 3 页
上一页
下一页
药物
反馈